| Size | Price | Stock | Qty |
|---|---|---|---|
| 15mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Goralatide targets primitive hematopoietic stem cells and progenitors. It functions as a physiological regulator of hematopoiesis by inhibiting the entry of hematopoietic stem cells into the S-phase of the cell cycle. Goralatide inhibits primitive hematopoietic cell proliferation. The compound is a physiological substrate of ACE, which cleaves and inactivates the tetrapeptide. By maintaining hematopoietic stem cells in a quiescent state, Goralatide plays a role in the regulation of hematopoietic homeostasis and may protect stem cells from damage during chemotherapy.
|
|---|---|
| ln Vitro |
In vitro, Goralatide inhibits the proliferation of primitive hematopoietic cells. The compound acts as a physiological regulator of hematopoiesis, maintaining hematopoietic stem cells in a quiescent state by preventing their entry into the S-phase of the cell cycle. Studies using hematopoietic stem cell cultures demonstrate that Goralatide reduces the proliferation of primitive progenitor cells while sparing more differentiated cells. The compound is also a substrate for ACE, which cleaves the tetrapeptide and regulates its activity. Goralatide is used as a research tool to study hematopoietic stem cell biology and regulation.
|
| ln Vivo |
In vivo, Goralatide acts as a physiological regulator of hematopoiesis. Studies in animal models demonstrate that Goralatide inhibits the proliferation of primitive hematopoietic cells and maintains stem cell quiescence. The compound has been investigated for its potential to protect hematopoietic stem cells from the cytotoxic effects of chemotherapy by keeping them in a quiescent state, thereby reducing chemotherapy-induced myelosuppression. Goralatide is also a substrate for ACE, which regulates its activity in vivo. Further studies are needed to fully characterize its in vivo efficacy.
|
| Enzyme Assay |
In vitro assays for Goralatide typically involve hematopoietic stem and progenitor cell cultures. The standard protocol includes isolating murine or human hematopoietic stem cells (Lin⁻Sca-1⁺c-Kit⁺ cells or CD34⁺ cells) and culturing them with Goralatide at concentrations ranging from 0.1-100 µM. Cell proliferation is assessed by thymidine incorporation, CFU (colony-forming unit) assays, or flow cytometry analysis of cell cycle status (Ki67 or BrdU staining). The ability of Goralatide to maintain stem cell quiescence is evaluated by measuring the proportion of cells in G₀ phase.
|
| Cell Assay |
Cell-based assays for Goralatide are conducted in hematopoietic stem and progenitor cell cultures. Cells are isolated from bone marrow or umbilical cord blood and cultured with Goralatide at varying concentrations (0.1-100 µM) for 24-72 hours. Cell cycle analysis is performed by flow cytometry using Ki67 and Hoechst or DAPI staining to distinguish G₀, G₁, and S/G₂/M phases. Proliferation is assessed by CFU assays in semisolid media (methylcellulose) with cytokines. Apoptosis is evaluated by Annexin V staining. The effects of Goralatide on stem cell differentiation are assessed by flow cytometry for lineage markers.
|
| Animal Protocol |
In vivo animal experiments for Goralatide typically use mouse models. Animals are administered Goralatide via subcutaneous or intraperitoneal injection at doses of 0.1-10 mg/kg. Bone marrow and peripheral blood are collected at various time points for analysis of hematopoietic stem and progenitor cell numbers, cell cycle status, and colony-forming ability. The compound's effects on chemotherapy-induced myelosuppression are evaluated by administering Goralatide before or after chemotherapy and measuring recovery of blood cell counts. The in vivo activity of Goralatide is also regulated by ACE-mediated cleavage.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Goralatide are limited. As a tetrapeptide, the compound is expected to have rapid clearance due to proteolytic degradation, particularly by ACE which cleaves Ac-SDKP. The compound has a short half-life in circulation. Goralatide acetate is a peptide that may require formulation for in vivo administration. Storage: typically at -20°C for long-term storage. Purity is typically >98%. The compound is soluble in aqueous solutions and DMSO. Further PK studies would be required for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
Toxicity data for Goralatide acetate are limited. The compound is a natural tetrapeptide and physiological regulator of hematopoiesis. It is supplied for research use only and is not intended for human administration. As a peptide, it is expected to have low toxicity. Standard laboratory safety precautions should be followed. No specific toxicological studies have been published. The compound should be handled with care and stored appropriately.
|
| References |
|
| Additional Infomation |
Goralatide acetate (Ac-SDKP) is a research compound supplied for laboratory use only. It is not an approved drug and has no clinical trial or marketing authorization status. The compound is a natural tetrapeptide that functions as a physiological regulator of hematopoiesis. It inhibits primitive hematopoietic cell proliferation and is a substrate for ACE. Purity is typically >98%. The compound appears as a white to off-white solid and should be stored appropriately.
|
| Molecular Formula |
C22H37N5O11
|
|---|---|
| Molecular Weight |
547.56
|
| Related CAS # |
Goralatide TFA;1796568-94-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8263 mL | 9.1314 mL | 18.2628 mL | |
| 5 mM | 0.3653 mL | 1.8263 mL | 3.6526 mL | |
| 10 mM | 0.1826 mL | 0.9131 mL | 1.8263 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
